Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Buck Braden

Psychiatry Burlington, NC Doctor of Osteopathy

NPI 1124345988 CMS profile 1397898

2732 Ann Elizabeth Dr, Burlington, NC 27215

Open in the dashboard

General payments

$4,137

241 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Buck Braden of Burlington, NC is reported in the CMS Open Payments database as having received $4,137 across 241 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,263 60
2024 General $851 42
2023 General $300 21
2022 General $237 12
2021 General $165 10
2020 General $464 29
2019 General $858 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Buck Braden
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Buck Braden were reported at $1,263. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Buck Braden Psychiatry median Middle half National median
2019 $858 $184 $59–$605 $163
2020 $464 $119 $36–$372 $114
2021 $165 $143 $43–$576 $132
2022 $237 $153 $50–$590 $149
2023 $300 $170 $56–$651 $160
2024 $851 $179 $57–$673 $164
2025 $1,263 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $675 33 payments
  2. Otsuka America Pharmaceutical, Inc. $468 30 payments
  3. AbbVie, Inc. $380 24 payments
  4. Lundbeck LLC $348 19 payments
  5. Neurocrine Biosciences, Inc. $338 15 payments
  6. Sunovion Pharmaceuticals Inc. $321 25 payments
  7. Janssen Pharmaceuticals, Inc $320 22 payments
  8. Alkermes, Inc. $300 17 payments
  9. ITI, Inc. $222 10 payments
  10. Indivior Inc. $203 11 payments
  11. Other $562 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,023 239 payments
  2. Education $115 2 payments
Products named General payments · program years 2019–2025
  1. UZEDY $364 21 payments
  2. ABILIFY MAINTENA $336 19 payments
  3. VRAYLAR $334 22 payments
  4. LATUDA $321 25 payments
  5. ARISTADA Cns $275 16 payments
  6. ARISTADA Cns $275 16 payments
  7. INVEGA SUSTENNA $265 18 payments
  8. ARISTADA Cns $250 15 payments
  9. ARISTADA Cns $250 15 payments
  10. ABILIFY ASIMTUFII $216 11 payments
  11. Other $2,606 149 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

312

Median for Psychiatry: 574

Drug cost

$116,721

Median for Psychiatry: $27,624

Branded share of claims

29.2%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 23 $69,222
Vraylar Cariprazine Hcl Brand 25 $37,805
Dayvigo Lemborexant Brand 14 $3,986
Fluphenazine Decanoate Generic 12 $1,229
Atomoxetine Hcl Generic 16 $1,214
Olanzapine Generic 28 $927
Quetiapine Fumarate Generic 35 $635
Divalproex Sodium Er Divalproex Sodium Brand 18 $535
Lamotrigine Generic 41 $254
Amitriptyline Hcl Generic 12 $231

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$2,536

Medicare's payments for the services billed

Medicare patients

14

Average age 53

Services billed

38

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Atrial fibrillation 0%
Chronic kidney disease 0%
Cancer 0%
Osteoporosis 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UZEDY
  • Teva Pharmaceuticals USA, Inc. $195
$195 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $170
$170 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $93
$93 — —
ABILIFY ASIMTUFII
  • Otsuka America Pharmaceutical, Inc. $63
$63 — —
VRAYLAR
  • AbbVie, Inc. $62
$62 25 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

241 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record